BioVersys AG (FRA:W33) Common Stock: €6.27 Mil (As of Dec. 2025)


FRA:W33 BioVersys AG FRA:W33
16 GF Score
Price €28.80
View Full Analysis

What is BioVersys AG Common Stock?

BioVersys AG FRA:W33 +0.70% 16 Common Stock is €6.27 Mil as of Dec. 2025. GuruFocus rates FRA:W33 with a GF Score™ of 16/100.

BioVersys AG's quarterly common stock increased from Dec. 2024 (€3.96 Mil) to Jun. 2025 (€6.22 Mil) and increased from Jun. 2025 (€6.22 Mil) to Dec. 2025 (€6.27 Mil).

BioVersys AG's annual common stock increased from . 20 (€0.00 Mil) to Dec. 2024 (€3.96 Mil) and increased from Dec. 2024 (€3.96 Mil) to Dec. 2025 (€6.27 Mil).

BioVersys AG Common Stock Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Common Stock Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Common Stock
3.96 6.27

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Common Stock 0.00 3.96 6.22 6.27
FRA:W33
16GF Score
BioVersys AG FRA:W33
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €6.27 Mil mean?
BioVersys AG (FRA:W33) has a Common Stock of €6.27 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on BioVersys AG and its competitors.
Is BioVersys AG's Common Stock too high?
BioVersys AG's current Common Stock is €6.27 Mil. Overall, BioVersys AG has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Common Stock compare to VRTX and REGN?
BioVersys AG's Common Stock of €6.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on BioVersys AG and its competitors. BioVersys AG's current Common Stock is €6.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (FRA:W33) has a current Common Stock of €6.27 Mil. The current Common Stock is €6.27 Mil. BioVersys AG's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For BioVersys AG (FRA:W33), the current Common Stock is €6.27 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKBIOV:Switzerland
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
16GF Score

Get the complete analysis for FRA:W33

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.80
Price